Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06104592 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL

StatusRecruiting
PhasePhase 2
Started2023-11-08
View on ClinicalTrials.gov ↗

Amendment history

2026-03-30
Study Status, Contacts/Locations v7
Re-verified, no change to tracked fields
2026-01-07
Study Status v6
Primary completion date2025-11→2026-12
Completion date2026-11→2026-12
2025-09-29
Study Status, Contacts/Locations v5
Study sitescontacts updated at 1 of 1 site
2025-06-11
Study Status v4
Re-verified, no change to tracked fields
2025-03-12
Study Status v3
Primary completion date2025-07→2025-11
Completion date2026-07→2026-11
Show 2 earlier versions
2024-08-21
Study Status v2
Primary completion date2027-10→2025-07
Completion date2027-10→2026-07
2024-03-21
Study Status v1
Start date2023-10-20→2023-11-08
2023-10-26
Original filing
This is a phase 2, single-arm, open-label study to evaluate the safety and efficacy of comprehensive bridging radiation therapy prior to CD19 CAR T-cell therapy for large B-cell lymphoma patients with bulky disease, defined as any lesion ≥5 cm.
Trial Details
NCT Number NCT06104592
Lead Sponsor H. Lee Moffitt Cancer Center and Research Institute
Collaborators: Kite, A Gilead Company
Conditions Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
Enrollment 27 participants
Start Date 2023-11-08
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-31